Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miles P Sparrow

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Digestive Diseases and Sciences|January 10, 2022
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness MethodologyGaurav Syal, Miles P Sparrow, Fernando Velayos, et al.
Alimentary Pharmacology & Therapeutics|August 15, 2020
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel diseaseAbhinav Vasudevan, Nina Parthasarathy, Danny Con, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2021
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonatesEmma Flanagan, Emily K Wright, Winita Hardikar, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Plos One|July 29, 2016
B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab TherapyWilhelmina M C Timmermans, Jan A M van Laar, Tim B van der Houwen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
The American Journal of Gastroenterology|July 15, 2024
When Perfect Is the Enemy of Good: Results of a RAND Appropriateness Panel on Treat to Target in Asymptomatic Inflammatory Bowel DiseaseHannah K Systrom, Victoria Rai, Siddharth Singh, et al.
Digestive Diseases and Sciences|January 10, 2022
Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness MethodologyGaurav Syal, Miles P Sparrow, Fernando Velayos, et al.
Alimentary Pharmacology & Therapeutics|August 15, 2020
Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel diseaseAbhinav Vasudevan, Nina Parthasarathy, Danny Con, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit allGil Y Melmed, Brennan M Spiegel, Brian Bressler, et al.
Alimentary Pharmacology & Therapeutics|February 20, 2021
Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonatesEmma Flanagan, Emily K Wright, Winita Hardikar, et al.
Inflammatory Bowel Diseases|April 9, 2016
Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness PanelShane M Devlin, Gil Y Melmed, Peter M Irving, et al.
Journal of Gastroenterology and Hepatology|October 10, 2025
IBD 2024: Charting a New Course in IBD Proceedings of the Takeda Symposium 22-23 November 2024 W Hotel, Brisbane, Queensland, AustraliaUma Mahadevan, Vipul Jairath, Jakob Begun, et al.
Journal of Crohn'S & Colitis|February 18, 2021
Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT IIWalter Reinisch, William J Sandborn, Silvio Danese, et al.
Plos One|July 29, 2016
B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab TherapyWilhelmina M C Timmermans, Jan A M van Laar, Tim B van der Houwen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesKonstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Pageof 10